Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

Webcasts

Fri 25 Sept / 14:00 - 16:00 / Hall A5

Prognostic markers for renal cell carcinoma (RCC) can support patient counseling and trial design; however, there are currently no predictive markers to guide therapy selection. Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for first-line treatment of advanced RCC have comparable efficacy, making tolerability and patient preference important factors. In the PISCES study, patients preferred pazopanib over sunitinib in this setting. The choice between everolimus and axitinib following prior VEGFR TKI should consider efficacy and potential for cumulative toxicity.

This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.

Fri 25 Sept / 17:00 - 19:00 / Hall A4

The multi-kinase inhibitor regorafenib is approved for treatment of patients with mCRC who were previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. In this symposium, experts share their real-world clinical experiences, using a case-based format, to guide appropriate patient selection and illustrate the clinical benefit of treatment with regorafenib. Proactive adverse event management strategies for patients receiving regorafenib treatment are also provided (G.MKT.SM.ON.10.2015.1417).

Sat 26 Sept / 13:00 - 14:30 / Hall A4

In the past decade, we have witnessed dramatic advances in the clinical research and management of metastatic castrate resistant prostate cancer (mCRPC) and this educational event will offer attendees an opportunity to discuss the latest strategies for optimizing mCRPC treatment. Several agents have been proven to extend overall survival and clinicians have more treatment options than ever before. Nevertheless, considerable controversy remains over how best to sequence therapies, the optimal use of imaging techniques, and the appropriate interpretation of biomarkers when evaluating treatment response. The Symposium program will use real-world clinical cases to illustrate the latest treatment approaches, providing attendees with a great opportunity to discuss challenging clinical situations directly from the practices of our panel of international experts.

Sat 26 Sept / 19.00 to 20:30 / Hall A2

This webcast discusses how to build on existing targeted treatment successes for HER2+ and HR+ ABC and inform the next-generation of treatment combinations. Critical signalling pathways in HR+ ABC are reviewed, and investigational treatment combinations targeting the CDK4/6 or PI3K/mTOR pathways are explored.

This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.

Sat 26 Sept / 19:00 - 20:30 / Lehar 3

What is the treatment goal in metastatic disease? Suppressing the tumour? Controlling the disease?

This is a very relevant question in today’s management of metastatic breast cancer and non-small cell lung cancer that a distinguished faculty addressed during an Official Satellite Symposium sponsored by Pierre Fabre Médicament at the 2015 European Cancer Congress.

During this meeting, the faculty addressed practical issues, such as maintenance therapy, optimal schedules, based both upon published clinical evidence and their own practice.

Sun 27 Sept. / 13:00 to 14:30 / Hall A4

Increased understanding of the molecular pathogenesis of cancer has led to development of several multikinase inhibitors (MKIs) designed to target specific molecular alterations and dysregulations of oncogenic pathways implicated in tumorigenesis. In the past decade, MKIs such as sorafenib, which targets vascular endothelial growth factor receptor–mediated tumor angiogenesis, have been approved for various tumor types, including renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). More recently, MKIs have also demonstrated efficacy in patients with differentiated thyroid cancer (DTC) who are refractory to radioactive iodine (RAI) therapy.

Sat 26 Sept / 13:00 - 14:30 / STOLZ 1

This interactive CME-certified webcast contains video and downloadable slides from the symposium Targeting Hypoxia to Unlock New Therapeutic Opportunities for Solid Tumors a prIME Oncology educational activity that was held on 26 September 2015 at the European Cancer Congress 2015 in Austria, Vienna.

Mon 28 Sept / 19:00 – 20:30 / Hall A2

Angiogenesis plays an important role in the progression of gastrointestinal (GI) malignancies. Anti-angiogenic treatments have improved the overall survival of patients with these cancers. The introduction of new anti-angiogenic agents warrants both exploration of the latest clinical data and discussion on how treatments involving anti-angiogenic drugs can be used to optimize outcomes in this patient group.